Ondansetron for irritable bowel syndrome with diarrhoea: randomised controlled trial
(2023)
Journal Article
Background: Irritable bowel syndrome with diarrhoea is characterised by frequent, loose or watery stools with associated urgency, resulting in marked reduction of quality of life. Ondansetron, a 5-hydroxytryptamine-3 receptor antagonist, has been sho... Read More about Ondansetron for irritable bowel syndrome with diarrhoea: randomised controlled trial.